Atrial fibrillation is the most common sustained heart rhythm disorder in the world, and it affects millions of Americans — recent estimates suggest at least 10 million U.S. adults are living with it, a number expected to keep climbing as the population ages. According to the CDC, atrial fibrillation — commonly called AFib or AF — is far from benign: untreated AFib substantially increases the risk of stroke, roughly doubles the risk of heart-related death, and raises the likelihood of developing heart failure. For a broader look at common health conditions, see our medical conditions guide.
The essentials: Atrial fibrillation is a fast, irregular heartbeat caused by chaotic electrical activity in the heart’s upper chambers. It often causes no symptoms and is frequently discovered by chance, but its most serious risk is stroke, because blood can pool and clot in the heart. Clinicians use the CHA2DS2-VASc score to decide who needs a blood thinner (anticoagulant) to prevent stroke; for most people, direct oral anticoagulants (DOACs) are preferred over warfarin, though warfarin is still used for mechanical heart valves and moderate-to-severe mitral stenosis. Management also involves controlling the heart rate or restoring normal rhythm and treating underlying drivers like high blood pressure, obesity, sleep apnea, and alcohol use. Never start or stop anticoagulation on your own — that decision belongs with your clinician.
Call 911 / seek emergency care now if AFib is accompanied by any of the following: chest pain or pressure, severe or sudden shortness of breath, fainting or near-fainting, or signs of a stroke — remember FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911. A very fast, pounding heartbeat with lightheadedness also warrants urgent evaluation. When in doubt, treat it as an emergency and let medical professionals sort it out.
What Is Atrial Fibrillation?
In a healthy heart, electrical signals originate in the sinoatrial (SA) node and travel through the atria (upper chambers) and ventricles (lower chambers) in an orderly sequence, producing a regular heartbeat of about 60 to 100 beats per minute at rest. In atrial fibrillation, the electrical signals in the atria become chaotic and disorganized. Instead of contracting in a coordinated way, the atria quiver, or fibrillate, extremely rapidly.
The AV node (the electrical gateway between the atria and ventricles) filters these chaotic signals, but enough get through to make the ventricles beat irregularly and often faster than normal. This irregular, frequently rapid heartbeat reduces the heart’s pumping efficiency and allows blood to pool in the atria, creating the conditions for blood clots to form — clots that can travel to the brain and cause a stroke.
The NHLBI and current guidelines describe AFib in patterns based on how long episodes last: paroxysmal (episodes that come and go, generally lasting less than seven days), persistent (episodes lasting more than seven days that require intervention to stop), long-standing persistent (continuous AFib lasting more than 12 months), and permanent (when patient and clinician decide to accept the rhythm and focus on rate control rather than trying to restore normal rhythm). AFib tends to progress over time from paroxysmal toward more sustained forms.
The 2023 ACC/AHA/ACCP/HRS guideline also frames AFib as a spectrum of disease with stages — from being at risk for AFib (because of factors like high blood pressure or obesity), to pre-AFib (structural changes such as an enlarged left atrium), to clinical AFib, and finally permanent AFib. The point of this staging is practical: it emphasizes that prevention and treating risk factors matter at every step, not just after AFib appears.
Causes and Risk Factors
Age is the strongest risk factor — AFib is relatively uncommon before age 50 but rises sharply with each subsequent decade, and lifetime risk is roughly 1 in 3 to 1 in 4 for adults. Hypertension is the most common modifiable risk factor and is present in a large majority of AFib patients. Other cardiovascular conditions that predispose to AFib include coronary artery disease, valvular heart disease (especially mitral valve disease), heart failure, and congenital heart defects.
Obesity is an increasingly recognized and important risk factor, partly through structural changes to the atria and partly through associated conditions like sleep apnea and inflammation. Obstructive sleep apnea is common among people with AFib and significantly worsens outcomes if untreated. Diabetes, thyroid disorders (particularly an overactive thyroid), chronic kidney disease, and excessive alcohol consumption (“holiday heart syndrome”) also increase risk.
According to the Mayo Clinic, endurance athletes paradoxically face a higher risk of AFib — likely due to structural remodeling of the atria from years of intense training. Family history plays a role, with genetic studies identifying multiple susceptibility loci. In some cases no clear cause is found, a situation sometimes called “lone AFib,” though this label is used less as we recognize more subtle contributors.
Symptoms
AFib symptoms vary widely. Some people experience a racing, fluttering, or pounding sensation in the chest (palpitations), along with fatigue, shortness of breath, dizziness, lightheadedness, reduced exercise tolerance, and chest discomfort. Others — particularly older adults — may have no symptoms at all, with AFib discovered incidentally during a routine exam, on a blood pressure monitor, or only after a stroke. Because “silent” AFib is common, an irregular pulse deserves attention even when you feel fine.
The intermittent nature of paroxysmal AFib makes detection challenging. Episodes may last seconds or days, and symptoms may be subtle enough to dismiss. Smartwatches and consumer ECG devices have increasingly flagged possible AFib in people who would not otherwise have been diagnosed. These tools can be a useful prompt to see a clinician, but a wearable alert is not a diagnosis — AFib is confirmed with a medical ECG, and the significance of very brief, device-detected episodes is still being studied.
The American Heart Association recommends checking your pulse periodically — an irregular pulse can be the first clue to AFib. If you notice persistent irregularity, even without other symptoms, see your doctor.
The Stroke Connection
Stroke prevention is the single most critical aspect of AFib management. When the atria fibrillate instead of contracting normally, blood pools and can form clots — particularly in a pouch called the left atrial appendage. If a clot breaks free and travels to the brain, it causes an ischemic stroke. AFib-related strokes tend to be more severe and more disabling than strokes from other causes.
The CHA2DS2-VASc score is the standard tool for estimating stroke risk in AFib. It assigns points for Congestive heart failure, Hypertension, Age (65-74 or 75+), Diabetes, prior Stroke/TIA, Vascular disease, and female Sex. Higher scores mean higher annual stroke risk. In general, a higher score (roughly 2 or more in men, or 3 or more in women) supports anticoagulation, while a score of 1 falls into a “consider it” zone where the clinician weighs individual factors. Current guidance increasingly frames the decision around a person’s estimated annual stroke risk rather than a single cutoff. This is a shared decision between you and your clinician — the score guides, but does not dictate, treatment.
According to the Cleveland Clinic, a substantial share of ischemic strokes are attributable to AFib. The tragedy is that many of these strokes are preventable with appropriate anticoagulation.
Blood Thinners for Stroke Prevention
Direct oral anticoagulants (DOACs) — including apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) — are now the preferred blood thinners for most people with AFib. They are at least as effective as warfarin at preventing stroke and generally carry a lower risk of intracranial hemorrhage (the most feared bleeding complication). They require no routine blood-level monitoring and have fewer food and drug interactions.
Warfarin (Coumadin) remains the right choice in specific situations — most importantly for patients with mechanical heart valves and those with moderate-to-severe mitral stenosis, where DOACs are not recommended. Warfarin requires regular blood testing (INR monitoring) to keep the blood appropriately thinned — too little increases stroke risk, too much increases bleeding risk. The therapeutic range is narrow, and diet, other medications, and illness can push the level out of range. Which anticoagulant is appropriate is a clinical decision based on your specific heart and health.
A crucial safety point: do not start or stop an anticoagulant on your own. Stopping a blood thinner without medical guidance can leave you unprotected against a stroke, even if your rhythm feels normal. If you have concerns about bleeding, cost, or side effects, talk to your clinician about options rather than simply discontinuing.
For patients who genuinely cannot take long-term blood thinners (for example, because of a high bleeding risk), left atrial appendage occlusion (LAAO) devices — such as the WATCHMAN — offer an alternative. These are implanted during a catheter-based procedure and seal off the left atrial appendage, the site where most AFib-related clots form. Studies have shown these devices to be a reasonable option for selected patients who cannot tolerate anticoagulation. Understanding healthcare costs can help when comparing long-term medication costs to procedural alternatives.
Rate Control vs. Rhythm Control
Beyond stroke prevention, AFib management focuses on either controlling the heart rate (allowing AFib to continue but keeping the rate within a reasonable range) or restoring and maintaining normal sinus rhythm. Importantly, choosing rhythm control does not remove the need for anticoagulation in people whose stroke risk warrants it.
Rate Control
Rate control uses medications — such as beta-blockers (for example, metoprolol), certain calcium channel blockers (diltiazem, verapamil), or digoxin — to slow the heart rate during AFib toward a target range. This approach does not eliminate AFib but reduces symptoms and protects the heart from the strain of a prolonged rapid rate. For many patients, particularly older adults with minimal symptoms, rate control is a reasonable and simpler strategy. Specific medications and doses are individualized by a clinician.
Rhythm Control
Rhythm control aims to restore normal sinus rhythm through electrical cardioversion (a brief, synchronized shock delivered under sedation), antiarrhythmic medications (such as flecainide, propafenone, amiodarone, sotalol, or dofetilide, each chosen for specific patients), or catheter ablation. Evidence — particularly the EAST-AFNET 4 trial — supports early rhythm control (within about a year of diagnosis) to reduce cardiovascular events in appropriate patients, which has shifted guidelines toward earlier, more proactive rhythm management.
Catheter ablation involves threading catheters to the heart and creating targeted lesions that electrically isolate the triggers of AFib (usually originating from the pulmonary veins). Success rates for maintaining sinus rhythm at one year are generally higher for paroxysmal AFib than for persistent AFib, and repeat procedures are sometimes needed. Current guidance considers ablation a reasonable first-line rhythm-control option for selected patients — especially younger, symptomatic people with paroxysmal AFib — and it has a particularly strong role in patients who also have heart failure with reduced ejection fraction.
Pulsed-Field Ablation: A Newer Approach
A significant recent development is pulsed-field ablation (PFA), which uses short bursts of electrical energy to ablate heart tissue through a mechanism (irreversible electroporation) that is more selective for heart-muscle cells. Because it is more tissue-selective, PFA is designed to reduce the risk of damage to nearby structures such as the esophagus and the phrenic nerve. Several PFA systems have received FDA approval and entered wider clinical use, and it has quickly become an important tool for AFib ablation. As with any newer technology, your electrophysiologist can explain whether it is available and appropriate for your situation and what the current evidence shows.
Lifestyle and Risk-Factor Modification
Modern guidelines treat aggressive risk-factor modification as a core pillar of AFib care — not an afterthought. Weight loss in people with obesity and AFib can reduce AFib burden, symptoms, and recurrence after ablation. The LEGACY study found that sustained weight loss of 10% or more was associated with a much greater probability of long-term freedom from AFib compared with those who lost little.
Alcohol reduction or elimination decreases AFib episodes; the ALCOHOL-AF trial found that abstinence in moderate drinkers with AFib significantly reduced recurrence. Treating sleep apnea (for example, with CPAP) improves AFib outcomes and reduces recurrence after cardioversion and ablation. Regular moderate exercise is beneficial, though extreme, sustained endurance exercise may be counterproductive for some people.
Managing underlying conditions — controlling blood pressure, blood sugar, and cholesterol, and treating thyroid disorders — is fundamental. Reducing excess caffeine is commonly advised, though current evidence suggests moderate coffee consumption does not worsen AFib for most people. Stress management may help, since surges in the “fight or flight” nervous system can trigger episodes in some individuals.
Frequently Asked Questions
Can atrial fibrillation go away on its own?
Paroxysmal AFib episodes do stop on their own, sometimes within minutes to hours. However, the underlying tendency for AFib usually persists and often worsens over time. Some people who address reversible drivers (such as losing significant weight, treating sleep apnea, or stopping alcohol) may see their AFib become much less frequent. True permanent resolution without any treatment is uncommon, and even if episodes stop, your stroke-prevention plan should only change with your clinician’s input.
Do I need to take blood thinners for life?
For most people with AFib and a CHA2DS2-VASc score that warrants anticoagulation, blood thinners are recommended indefinitely — even if normal rhythm is restored — because AFib can recur silently and the consequences of a stroke are severe. The decision to continue or stop anticoagulation should be made only with your cardiologist after careful risk assessment. Do not stop on your own.
Can I still exercise with AFib?
Usually, yes. Regular moderate exercise is encouraged for most people with AFib — it improves fitness, helps with weight management, and may reduce AFib burden. Activities like walking, cycling, and swimming are generally safe. Discuss your exercise plans with your doctor, especially if your heart rate is not well controlled. Extreme endurance training may warrant more individualized guidance.
Is AFib hereditary?
Genetics contribute to AFib risk — having a first-degree relative with AFib roughly doubles your risk, and researchers have identified multiple associated genetic variants. However, modifiable risk factors (particularly hypertension, obesity, and sleep apnea) are far more impactful for most people, which means you can meaningfully reduce your risk regardless of family history.
What is the difference between AFib and a heart attack?
AFib is a heart rhythm disorder — the heart beats irregularly but blood generally keeps flowing. A heart attack is caused by a blocked coronary artery that cuts off blood supply to part of the heart muscle. AFib can cause chest discomfort and shortness of breath that may mimic a heart attack. If you are unsure, treat it as a heart attack and call 911 — let medical professionals sort it out.
Taking Charge of Your AFib
Atrial fibrillation is manageable, but it requires active engagement. Take any prescribed blood thinner exactly as directed — skipping doses can dramatically increase stroke risk — and never stop it on your own. Monitor your pulse and report new or worsening symptoms promptly. Address the modifiable factors within your control: lose weight if needed, treat sleep apnea, limit alcohol, exercise regularly, and manage blood pressure.
Work with your cardiologist or electrophysiologist to determine whether rate control, rhythm control, or ablation — including newer options like pulsed-field ablation — is the right strategy for your specific situation. The treatment landscape for AFib has expanded significantly, and the options available today are more effective and safer than ever. With proper management, most people with AFib lead full, active lives.
Sources
- Centers for Disease Control and Prevention (CDC) — Atrial Fibrillation
- National Heart, Lung, and Blood Institute (NHLBI) — Atrial Fibrillation
- Mayo Clinic — Atrial Fibrillation: symptoms and causes
- American Heart Association (AHA) — Atrial Fibrillation: symptoms, treatment, and prevention
- Cleveland Clinic — Atrial Fibrillation (AFib)
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (Circulation / Journal of the American College of Cardiology)